Clinical Trials
Apitope Announces Positive Results with Novel Treatment for Graves’ Disease
Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases (including multiple sclerosis (MS), Graves' disease and uveitis), announced positive results...
Clinical Trials
Sanofi’s Toujeo® Max SoloStar® Receives FDA Approval
The U.S. FDA approved Sanofi's Toujeo® (insulin glargine 300 Units/mL) Max SoloStar®, the highest capacity long-acting insulin pen that will be available on the market....
Clinical Trials
GeNeuro and Servier announce successful 12-month results in neuroprotection for Phase 2b CHANGE-MS Study with GNbAC1 in Multiple Sclerosis
GeNeuro and Servier announced positive results at 12 months from the CHANGE-MS Phase 2b study of GNbAC1, a novel and promising therapeutic approach for the...
Clinical Trials
Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study Of ALXN1210 In Complement Inhibitor Treatment-Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria
Alexion Pharmaceuticals, Inc. announced that the pivotal Phase 3 study of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor, demonstrated non-inferiority to Soliris® (eculizumab) in...
Clinical Trials
Medigene strengthens its patent portfolio with a European patent covering T cell identification method
Medigene AG , a clinical stage immune-oncology company focusing on the development of T cell immuno-therapies for the treatment of cancer, announces the grant of...
Clinical Trials
Aimmune’s peanut succeeds at phase||| trials
U.S. drug developer Aimmune Therapeutics said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study, sending its shares...
Clinical Trials
AbbVie’s elagolix on a great roll in its PH3 trials
Clinical response was defined as menstrual blood loss volume of less than 80 mL during month six and a 50 percent or greater reduction in...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.